Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100OW0Q
Period2021-10-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Revenue¥36.2bn2020-10-01 → 2021-09-30Cons.Net sales (5-year summary)
Revenue¥27.2bn2020-10-01 → 2021-06-30Cons.Net sales
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Operating income¥572m2020-10-01 → 2021-06-30Cons.Operating income
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥759m2020-10-01 → 2021-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥608m2020-10-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥612m2020-10-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥517m2020-10-01 → 2021-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥428m2020-10-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Net income¥446m2020-10-01 → 2021-06-30Cons.Profit loss
Total assets¥15.0bnat 2022-06-30Cons.Assets
Total assets¥16.1bnat 2021-09-30Cons.Assets
Total assets¥16.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥8.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥9.8bnat 2021-09-30Cons.Liabilities
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥799mat 2021-09-30Cons.Cash and deposits
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥564.912020-10-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥467.382020-10-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥114.172021-04-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn
Otherother segmentsrevenue2020-10-01 → 2021-06-30¥331m
Otherother segmentsrevenue external2020-10-01 → 2021-06-30¥331m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2020-10-01 → 2021-06-30¥10.9bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2020-10-01 → 2021-06-30¥10.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2020-10-01 → 2021-06-30¥27.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-10-01 → 2021-06-30¥27.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member58900
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.061
Number of shares held in own name treasury shares etcCurrentQuarterInstant58900
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant58900
Shareholding ratio treasury shares etcCurrentQuarterInstant0.061
Cash and depositsPrior1YearInstant799184000JPY
Cash and depositsCurrentQuarterInstant1252623000JPY
Notes and accounts receivable tradePrior1YearInstant8528957000JPY
Notes and accounts receivable tradeCurrentQuarterInstant7332896000JPY
Electronically recorded monetary claims operating caPrior1YearInstant205909000JPY
Electronically recorded monetary claims operating caCurrentQuarterInstant270934000JPY
MerchandisePrior1YearInstant1030432000JPY
MerchandiseCurrentQuarterInstant1128708000JPY
Lease investment assets caPrior1YearInstant128231000JPY
Lease investment assets caCurrentQuarterInstant122379000JPY
Other caPrior1YearInstant310284000JPY
Other caCurrentQuarterInstant273883000JPY
Allowance for doubtful accounts caPrior1YearInstant-1875000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-2483000JPY
Current assetsPrior1YearInstant11001124000JPY
Current assetsCurrentQuarterInstant10378942000JPY
Buildings and structures netPrior1YearInstant505459000JPY
Buildings and structures netCurrentQuarterInstant486260000JPY
LandPrior1YearInstant1495006000JPY
LandCurrentQuarterInstant1495006000JPY
Lease assets net ppePrior1YearInstant141669000JPY
Lease assets net ppeCurrentQuarterInstant137877000JPY
Other net ppePrior1YearInstant320751000JPY
Other net ppeCurrentQuarterInstant329758000JPY
Property plant and equipmentPrior1YearInstant2462885000JPY
Property plant and equipmentCurrentQuarterInstant2448903000JPY
Lease assets iaPrior1YearInstant13904000JPY
Lease assets iaCurrentQuarterInstant3476000JPY
Software in progressPrior1YearInstant－JPY
Software in progressCurrentQuarterInstant21450000JPY
Other iaPrior1YearInstant8292000JPY
Other iaCurrentQuarterInstant8833000JPY
Intangible assetsPrior1YearInstant22197000JPY
Intangible assetsCurrentQuarterInstant33760000JPY
Investment securitiesPrior1YearInstant1710775000JPY
Investment securitiesCurrentQuarterInstant1430681000JPY
Lease investment assets ioaPrior1YearInstant200674000JPY
Lease investment assets ioaCurrentQuarterInstant113119000JPY
Other ioaPrior1YearInstant756285000JPY
Other ioaCurrentQuarterInstant652943000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-25372000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-25753000JPY
Investments and other assetsPrior1YearInstant2642363000JPY
Investments and other assetsCurrentQuarterInstant2170990000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-09-30pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-09-30pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2020-10-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2020-10-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-09-30pass
statement vs summary · total assetsconsolidated 2022-06-30pass